Pin1 inhibition improves the efficacy of ralaniten compounds that bind to the N-terminal domain of androgen receptor

Therapies for lethal castration-resistant prostate cancer (CRPC) are an unmet medical need. One mechanism underlying CRPC and resistance to hormonal therapies is the expression of constitutively active splice variant(s) of androgen receptor (AR-Vs) that lack its C-terminus ligand-binding domain. Tra...

Descripción completa

Detalles Bibliográficos
Autores principales: Leung, Jacky K., Imamura, Yusuke, Kato, Minoru, Wang, Jun, Mawji, Nasrin R., Sadar, Marianne D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7985297/
https://www.ncbi.nlm.nih.gov/pubmed/33753863
http://dx.doi.org/10.1038/s42003-021-01927-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7985297/
https://www.ncbi.nlm.nih.gov/pubmed/33753863
http://dx.doi.org/10.1038/s42003-021-01927-3

Ejemplares similares